Pomalidomide
- Generic Name
- Pomalidomide
- Brand Names
- Imnovid, Pomalyst, Imnovid (previously Pomalidomide Celgene), Pomalidomide Viatris, Pomalidomide Zentiva, Pomalidomide Krka, Pomalidomide Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C13H11N3O4
- CAS Number
- 19171-19-8
- Unique Ingredient Identifier
- D2UX06XLB5
- Background
Pomalidomide, an analogue of thalidomide, is an immunomodulatory antineoplastic agent. FDA approved on February 8, 2013.
- Indication
Pomalidomide is indicated for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and have demonstrated disease progression on or within 60 days of completion of the last therapy. It is also indicated for the treatment of Kaposi's sarcoma (KS) in AIDS patients who have failed highly active antiretroviral thera...
- Associated Conditions
- Kaposi's Sarcoma, Multiple Myeloma (MM)
- Associated Therapies
- -
Pomalidomide With Melphalan and Dexamethasone for Untreated Systemic AL Amyloidosis
- Conditions
- Interventions
- First Posted Date
- 2013-03-08
- Last Posted Date
- 2016-05-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 3
- Registration Number
- NCT01807286
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Pomalidomide or Lenalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Previously Treated With Lenalidomide
- Conditions
- Interventions
- First Posted Date
- 2013-02-18
- Last Posted Date
- 2018-08-21
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 9
- Registration Number
- NCT01794039
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Bendamustine + Pomalidomide + Dex in R/R Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2012-12-21
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- Cristina Gasparetto
- Target Recruit Count
- 56
- Registration Number
- NCT01754402
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
Pomalidomide and Dexamethasone Effects in Multiple Myeloma Patients With Del 17p or t (4;14)
- First Posted Date
- 2012-12-10
- Last Posted Date
- 2015-12-04
- Lead Sponsor
- University Hospital, Lille
- Target Recruit Count
- 63
- Registration Number
- NCT01745640
- Locations
- 🇫🇷
CHRU-Hôpital Sud Amiens, Amiens, France
🇫🇷Hôpital Haut-Leveque, PESSAC cedex, France
🇫🇷Chru Lille, Lille, France
Autologous Stem Cell Transplant With Pomalidomide (CC-4047®) Maintenance Versus Continuous Clarithromycin/ Pomalidomide / Dexamethasone Salvage Therapy in Relapsed or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2012-12-10
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 23
- Registration Number
- NCT01745588
- Locations
- 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸North Shore LIJ, New Hyde Park, New York, United States
🇺🇸Memorial Sloan Kettering Cancer Center @ Suffolk, Commack, New York, United States
Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2012-11-28
- Last Posted Date
- 2023-06-06
- Lead Sponsor
- Celgene
- Target Recruit Count
- 559
- Registration Number
- NCT01734928
- Locations
- 🇺🇸
Western Kentucky Hematology and Oncology Group, PSC, Paducah, Kentucky, United States
🇺🇸Local Institution - 132, Bangor, Maine, United States
🇺🇸St. Agnes - Medical Center, Baltimore, Maryland, United States
First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD
- Conditions
- Interventions
- First Posted Date
- 2012-11-19
- Last Posted Date
- 2023-05-09
- Lead Sponsor
- Barbara Ann Karmanos Cancer Institute
- Target Recruit Count
- 18
- Registration Number
- NCT01728259
- Locations
- 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
🇺🇸Colorado Blood Cancer Institute, Denver, Colorado, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma or Newly Diagnosed or Relapsed or Refractory Intraocular Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2012-11-06
- Last Posted Date
- 2019-07-22
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 29
- Registration Number
- NCT01722305
- Locations
- 🇺🇸
Dana-Farber Harvard Cancer Center, Boston, Massachusetts, United States
🇺🇸Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
🇺🇸Mayo Clinic in Arizona, Scottsdale, Arizona, United States
Evaluation of Safety of Pomalidomide in Combination With Dexamethasone (Low Dose) in Patients With Refractory or Relapsed and Refractory Multiple Myeloma
- First Posted Date
- 2012-10-24
- Last Posted Date
- 2022-01-10
- Lead Sponsor
- Celgene
- Target Recruit Count
- 682
- Registration Number
- NCT01712789
- Locations
- 🇦🇹
Medical University of Graz, Graz, Austria
🇦🇹Medizinische Universitat Innsbruck, Innsbruck, Austria
🇦🇹Wilhelminenspital Vienna, Vienna, Austria
A Phase 1 Open-Label Study to Evaluate the Effect of CYP450 and P-gp Inhibition and Induction on the Pharmacokinetics of Pomalidomide (CC-4047) in Healthy Male Subjects
- Conditions
- Interventions
- First Posted Date
- 2012-10-16
- Last Posted Date
- 2019-11-12
- Lead Sponsor
- Celgene
- Target Recruit Count
- 32
- Registration Number
- NCT01707407
- Locations
- 🇺🇸
Covance Research Unit, Inc, Madison, Wisconsin, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.